Cantor Fitzgerald Raises ADMA Biologics (NASDAQ:ADMA) Price Target to $15.00

ADMA Biologics (NASDAQ:ADMA) had its price objective increased by Cantor Fitzgerald from $10.00 to $15.00 in a research report sent to investors on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the biotechnology company’s stock.

A number of other equities analysts also recently weighed in on ADMA. Raymond James raised their target price on shares of ADMA Biologics from $8.00 to $10.00 and gave the company a strong-buy rating in a research note on Friday, May 10th. Mizuho raised their price target on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a buy rating in a research report on Thursday, June 20th. Finally, HC Wainwright raised their price target on shares of ADMA Biologics from $7.50 to $10.00 and gave the company a buy rating in a research report on Friday, May 10th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Buy and a consensus price target of $12.25.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $12.31 on Tuesday. ADMA Biologics has a fifty-two week low of $3.06 and a fifty-two week high of $12.47. The company has a 50 day simple moving average of $10.03 and a two-hundred day simple moving average of $7.16. The company has a market capitalization of $2.85 billion, a price-to-earnings ratio of -615.50 and a beta of 0.55. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.86 and a current ratio of 5.21.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.03. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. The business had revenue of $81.90 million during the quarter, compared to the consensus estimate of $77.28 million. During the same quarter last year, the firm earned ($0.03) earnings per share. The business’s revenue for the quarter was up 43.9% on a year-over-year basis. Analysts expect that ADMA Biologics will post 0.35 EPS for the current fiscal year.

Insider Activity at ADMA Biologics

In related news, CEO Adam S. Grossman sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $10.72, for a total value of $1,072,000.00. Following the sale, the chief executive officer now owns 2,081,475 shares in the company, valued at $22,313,412. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 3.70% of the stock is owned by insiders.

Institutional Investors Weigh In On ADMA Biologics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ADMA. EntryPoint Capital LLC purchased a new stake in ADMA Biologics in the first quarter worth approximately $31,000. Simplicity Wealth LLC purchased a new position in shares of ADMA Biologics during the 1st quarter worth $68,000. AJOVista LLC purchased a new position in shares of ADMA Biologics during the 4th quarter worth $77,000. Oxford Asset Management LLP purchased a new position in shares of ADMA Biologics during the 4th quarter worth $83,000. Finally, CWM LLC boosted its stake in shares of ADMA Biologics by 114.2% during the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after acquiring an additional 4,367 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.